AI Summary
✦ ClarthaValuation Metrics
Trading 0.2% above historical median. Valuation is stable — currently in the undervalued zone (z-score: -0.05). Confidence: 86%.
Forward outlook is unavailable because live next-12-month estimate data is not available for this ticker right now.
5Y Average
11.25
Current
13.60
Overvalued
14.72
Undervalued
12.49
5Y Average
8.08
Current
9.77
Overvalued
9.94
Undervalued
5.63
5Y Average
1.47
Current
1.78
Overvalued
1.69
Undervalued
1.25
Peers & Comparison
Sector: Health Care · Theme: Pharmaceuticals
| Company | Rev. Growth | Margin | P/E | vs Avg | 52W Perf. |
|---|---|---|---|---|---|
LARSEN & TOUBRO LTD. LTPharmaceuticals | +8.1% | 5.6% | 33.4x Undervalued | -23% vs avg | +10.7% |
ZYDUS LIFESCIENCES LTD ZYDUSLIFEPharmaceuticals | +16.2% | 18.6% | 23.0x Undervalued | -47% vs avg | +17.1% |
MANKIND PHARMA LIMITED MANKINDPharmaceuticals | +12.9% | 13.9% | 49.4x Fair | +13% vs avg | +0.3% |
GLENMARK PHARMACEUTICALS GLENMARKPharmaceuticals | +23.1% | 10.1% | 36.2x Undervalued | -17% vs avg | +9.4% |
ABBOTT INDIA LIMITED ABBOTINDIAPharmaceuticals | +6.5% | 22.4% | 38.3x Fair | -12% vs avg | -15.4% |
AJANTA PHARMA LIMITED AJANTPHARMPharmaceuticals | +24.8% | 19.6% | 39.3x Fair | -10% vs avg | +30.0% |
IPCA LABORATORIES LTD IPCALABPharmaceuticals | +6.3% | 11.8% | 39.4x Fair | -10% vs avg | +22.5% |
LAURUS LABS LIMITED LAURUSLABSPharmaceuticals | +29.1% | 15.0% | 90.2x Premium | +107% vs avg | +123.1% |
Comparable-scale peer data is limited — showing nearest stored business/industry peers instead of an empty comparison.
Financials
Real statement data for revenue, earnings quality, conversion, and balance-sheet coverage. Monetary values are shown in Rs crore.
Latest revenue
₹187 CrMar 2026Latest net profit
₹12 CrMar 2026Latest EPS
₹5.81Mar 2026Net margin
13.0%Mar 2026Performance
Bars show revenue and net profit. The line shows net margin.
- Revenue
- Net income
- Net margin %
Earnings
Revenue is shown in crores. EPS is rupees per share.
- Revenue
- EPS
Revenue to profit conversion
Bridge from operating numbers to profit for the latest reported period.
Latest reported period: Mar 2026
Debt level and coverage
Debt, cash and free cash flow compared on the same crore scale.
- Debt
- Free cash flow
- Cash & equivalents
Results
| Metric | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 112 | 136 | 156 | 146 | 142 | 147 | 161 | 147 | 168 | 154 | 163 | 166 | 187 |
| Expenses + | 96 | 115 | 125 | 117 | 124 | 125 | 133 | 123 | 141 | 130 | 138 | 143 | 162 |
| Operating Profit | 17 | 21 | 31 | 30 | 18 | 23 | 28 | 24 | 27 | 24 | 25 | 24 | 25 |
| OPM % | 15% | 15% | 20% | 20% | 13% | 15% | 18% | 16% | 16% | 15% | 16% | 14% | 13% |
| Other Income + | 4 | 8 | 9 | 11 | 7 | 10 | 10 | 9 | -7 | 15 | 7 | 15 | -4 |
| Interest | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 2 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 4 | 4 | 4 |
| Profit before tax | 17 | 25 | 37 | 38 | 22 | 29 | 35 | 29 | 16 | 35 | 29 | 35 | 17 |
| Tax % | 26% | 25% | 25% | 26% | 16% | 20% | 24% | 28% | 29% | 22% | 31% | 18% | 30% |
| Net Profit + | 13 | 19 | 28 | 28 | 19 | 24 | 26 | 21 | 12 | 28 | 20 | 29 | 12 |
| EPS in Rs | 6.27 | 9.49 | 13.80 | 14.00 | 9.29 | 11.82 | 13.15 | 10.37 | 5.78 | 13.82 | 9.98 | 14.28 | 5.81 |
| Raw PDF |
All values in ₹ Crores unless otherwise stated. Source: Screener Master (Standalone).
Events Timeline
Board Meeting Intimation for Board Meeting Intimation For Consideration And Approving The Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter Ended June 30, 2026.
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018